Phase II study of nimustine, carboplatin, vincristine, and interferon-β with radiotherapy for glioblastoma multiforme: Experience of the Kyoto Neuro-Oncology Group

Journal of Neurosurgery

Volumn 105, Issue 3, 2006, Pages 385-391

  Aoki, Tomokazu ^a   Takahashi, Jun A ^b   Ueba, Tetsuya ^b   Oya, Natsuo ^b   Hiraoka, Masahiro ^b   Matsui, Kunihiko ^b   Fukui, Tsugiya ^b   Nakashima, Yasuaki ^b   Ishikawa, Masatsune ^b   Hashimoto, Nobuo ^b  

^a Kitano Hospital   (Japan)

^b NONE

Author keywords

Carboplatin; Chemotherapy; Glioblastoma multiforme; Interferon ; Nimustine; Vincristine

Indexed keywords

ANTIEMETIC AGENT; BETA INTERFERON; CARBOPLATIN; NIMUSTINE; VINCRISTINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; GLIOBLASTOMA; HUMAN; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; SENSORY NEUROPATHY; THROMBOCYTOPENIA; VOMITING;

EID: 33748497296     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/jns.2006.105.3.385     Document Type: Article

References (28)

1. Aoki T, Ishikawa M, Ueba T, Hashimoto N, Nakashima Y, et al: VAC-feron chemotherapy for glioblastoma. Neurol Med Surg 39:220, 1999
2. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, et al: Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23:2372-2377, 2005
3. DeAngelis LM, Burger PC, Green SB, Cairncross JG: Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol 44:691-695, 1998
4. Del Rowe J, Scott C, Werner-Wasik M, Bahary JP, Curran WJ, Fisher B: Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol 18:1254-1259, 2000
5. Fisher B, Won M, Macdonald D, Johnson DW, Roa W: Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. Int J Radiat Oncol Biol Phys 53:980-986, 2002
6. Glioma Meta-analysis Trialists (GMT) Group: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011-1018, 2002
7. Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, et al: Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 21:1485-1491, 2003
8. Grossman SA, Wharam M, Sheidler V, Kleinberg L, Zeltzman M, Yue N, et al: Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol 15:2596-2603, 1997
9. Huncharek M, Muscat J: Treatment of recurrent high grade astrocytoma; results of a systematic review of 1, 415 patients. Anticancer Res 18:1303-1311, 1998
10. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215-229, 2002
11. Kleinberg L, Grossman SA, Carson K, Lesser G, O'Neill A, Pearlman J, et al: Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II New Approaches to Brain Tumor Therapy CNS Consortium safety and efficacy study. J Clin Oncol 20:3149-3155, 2002
12. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
13. Matsutani M, Nakamura O, Nakamura M, Nagashima T, Asai A, Fujimaki T, et al: Radiation therapy combined with radiosensitizing agents for cerebral glioblastoma in adults. J Neurooncol 19:227-237, 1994
14. Medical Research Council Brain Tumor Working Party: Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 19:509-518, 2001
15. The Neuro-Oncology Working Group of the German Cancer Society: Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 21:3276-3284, 2003
16. Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, et al: Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 11:850-856, 1993
17. Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, et al: Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81:690-698, 1994
18. Sawaya R: Extent of resection in malignant gliomas: a critical summary. J Neurooncol 42:303-305, 1999
19. Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, et al: Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40:51-55, 1998
20. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, et al: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375-1382, 2002
21. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
22. Taguchi T: Clinical efficacy of lentinan on patients with stomach cancer: end point results of a four-year follow-up survey. Cancer Detect Prev Suppl 1:333-349, 1987
23. Takahashi Y, Nishioka K: Survival without tumor shrinkage: re-evaluation of survival gain by cytostatic effect of chemotherapy. J Natl Cancer Inst 87:1256-1257, 1995 (Letter)
24. Takakura K, Abe H, Tanaka R, Kitamura K, Miwa T, Takeuchi K, et al: Effects of ACNU and radiotherapy on malignant gliomas. J Neurosurg 64:53-57, 1986
25. Uji T, Ueba T, Kanou H, Kawabata Y, Nakakugi T, Takahashi J, et al: Analysis of combination chemotherapy and gene expression of chemoresistant gene in vitro. The 10th Annual Meeting of the Japan Society for Neuro-Oncology. 2001, p30 (Abstract) (Jpn)
26. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329, 1980
27. Walker MD, Strike TA, Sheline GE: An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5:1725-1731, 1979
28. Yoshida J, Kajita Y, Wakabayashi T, Sugita K: Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumor resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir (Wien) 127:55-59, 1994